EyeGene,Inc Logo

EyeGene,Inc

Develops gene/cell therapies for age-related diseases and preventive vaccines.

185490 | KO

Overview

Corporate Details

ISIN(s):
KR7185490000
LEI:
Country:
South Korea
Address:
경기도 의왕시 양지편2로 13 2층, 의왕시

Description

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-29 00:00
투자판단관련주요경영사항 (대상포진 백신 EGHZ 국내 기술이전 계약 해지 및 권리 정리)
Korean HTML 6.1 KB
2025-12-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 28.6 KB
2025-12-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 29.4 KB
2025-12-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.5 KB
2025-12-18 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.6 KB
2025-12-17 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 152.5 KB
2025-12-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.5 KB
2025-12-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 26.5 KB
2025-12-17 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.5 KB
2025-09-17 00:00
증권신고서(지분증권) (2025.11)
Korean HTML 1.8 MB
2025-09-16 00:00
주요사항보고서(유상증자결정)
Korean HTML 32.6 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean HTML 1.1 MB
2025-06-30 00:00
투자판단관련주요경영사항(임상시험계획승인신청등결정) (4가 수막구균 접합백신 ‘EGMCV4의 국내 임상 제2/3상 임상시…
Korean HTML 17.9 KB
2025-05-15 00:00
분기보고서 (2025.03)
Korean HTML 1.1 MB
2025-05-12 00:00
주식매수선택권부여에관한신고
Korean HTML 18.1 KB

Automate Your Workflow. Get a real-time feed of all EyeGene,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EyeGene,Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EyeGene,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Clinical-stage immuno-oncology company developing cell and gene therapies for cancer.
Sweden
ELIC
Elicio Therapeutics, Inc. Logo
Clinical-stage biotech developing lymph node-targeted immunotherapies for cancer.
United States of America
ELTX
E-Novia Logo
A venture studio and consultancy that transforms Physical AI research into products.
Italy
E9IA
Ensysce Biosciences, Inc. Logo
Clinical-stage pharma firm developing abuse-deterrent drugs for severe pain.
United States of America
ENSC
Enveric Biosciences, Inc. Logo
Develops novel small-molecule therapeutics for neuropsychiatric disorders.
United States of America
ENVB
Eone Diagnomics Genome Center Co., Ltd. Logo
A healthcare company specializing in genetic analysis for personalized medicine.
South Korea
245620
Develops hair loss therapies and provides preclinical CRO services.
South Korea
446440
Equillium, Inc. Logo
Clinical-stage biotech developing therapies for autoimmune & inflammatory disorders.
United States of America
EQ
Eurofins-Cerep Logo
Contract research organization for pre-clinical in vitro drug discovery services.
France
ALECR
Evaxion A/S Logo
A clinical-stage TechBio company developing immunotherapies using an AI platform.
United States of America
EVAX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.